The past 12 months have rocked the follow-on biopharmaceutical sector, with major new draft guidelines at last released by the FDA and the formation of a new wave of industry-leading strategic partnerships that will accelerate product development and commercialization.Recognizing the unprecedented and time-sensitive importance of these developments, the 13th annual Business of Biosimilars & Generic Drugs conference is now announcing an updated conference program that adds even more depth to our coverage of these crucial topics!
We would like to share our revamped & rebalanced program brochure. We have made it easier to catch every discussion related to the new FDA draft guidelines, and we have given you more opportunities to share strategic lessons on market access that apply to both biosimilars and small-molecule generics.
Take special note of the following key topics:
 |
| Speaker Richard Brudnick |
- - KEYNOTE: Richard Brudnick, Vice President, Co-Head Business Development / M&A, BIOGEN IDEC presenting “The Art of the Biotech Deal – Biogen Idec, Samsung, and the Future of Follow-On Biologics”
- - KEYNOTE: Suzanne Munck, Chief Counsel for Intellectual Property, FTC presenting “Turn Antitrust Laws to Your Advantage in the Generic and Biosimilar Market”
- - Dominic Marasco, Executive Vice President, Business Development, INVENTIV HEALTH presenting “Building the Necessary Goodwill for Successful Biosimilar Rollout”
The 13th Annual Business of Biosimilars and Generic Drugs will take place September 10-12, 2012 in Boston, MA. As a reader of this blog, you receive an exclusive discount of 25% off of the standard rate when you register to join us. Simply use priority code XP1786LINK. Have any questions about the event? Feel free to email Jennifer Pereira.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment